Open AccessRecombinant Human VEGF165b Inhibits Experimental Choroidal Neovascularization
Author(s) -
Jing Hua,
Christine Spee,
Satoru Kase,
Emma Rennel,
Anette Magnussen,
Yan Qiu,
Alexander H. R. Varey,
Sandeep Dhayade,
A Churchill,
Steven J. Harper,
David O. Bates,
David R. Hinton
Publication year - 2010
Publication title -
investigative ophthalmology and visual science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.935
H-Index - 218
eISSN - 1552-5783
pISSN - 0146-0404
DOI - 10.1167/iovs.09-4360
Subject(s) - choroidal neovascularization , vascular endothelial growth factor , macular degeneration , neovascularization , angiogenesis , ranibizumab , medicine , vascular endothelial growth factor a , pegaptanib , pathology , bevacizumab , cancer research , ophthalmology , vegf receptors , chemotherapy
Vascular endothelial growth factor (VEGF-A) is the principal stimulator of angiogenesis in wet age-related macular degeneration (AMD). However, VEGF-A is generated by alternate splicing into two families, the proangiogenic VEGF-A(xxx) family and the antiangiogenic VEGF-A(xxx)b family. It is the proangiogenic family that is responsible for the blood vessel growth seen in AMD.